Latest Breaking News On - Avego healthcare capital - Page 1 : comparemela.com

MedCity News Arch Oncology adds $105M for better way to get immune cells to gobble up tumors Several companies are developing immunotherapies targeting the “don’t eat me” cancer protein CD47. Arch Oncology, which is developing drugs with features that could set them apart from this field, now has $105 million for multiple clinical trials. Shares0   The first wave of cancer drugs that clear the way for a certain immune cell to gobble up tumors has yet to reach the market, but Arch Oncology is already developing what it calls the “next-generation” of this type of cancer immunotherapy and it has raised $105 million in fresh capital to advance multiple clinical tests of its lead asset.

United kingdomHong kongUnited statesWilliam frazierWashington universityGilead sciencesBroadfin holdingsRoche venture fundArch oncologyEventide asset managementCowen healthcare investmentsCalifornia based archMolecular cancer therapeuticsMenlo parkCalifornia based fortyCmab biopharma